HEADER VIRAL PROTEIN 19-JUN-20 6XHL TITLE COVALENT COMPLEX OF SARS-COV MAIN PROTEASE WITH N-[(2S)-1-({(2S,3S)-3, TITLE 2 4-DIHYDROXY-1-[(3S)-2-OXOPYRROLIDIN-3-YL]BUTAN-2-YL}AMINO)-4-METHYL- TITLE 3 1-OXOPENTAN-2-YL]-4-METHOXY-1H-INDOLE-2-CARBOXAMIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: 3C-LIKE PROTEINASE; COMPND 3 CHAIN: A, B; COMPND 4 EC: 3.4.22.69; COMPND 5 ENGINEERED: YES; COMPND 6 OTHER_DETAILS: N-[(2S)-1-({(2S,3S)-3,4-DIHYDROXY-1-[(3S)-2- COMPND 7 OXOPYRROLIDIN-3-YL]BUTAN-2-YL}AMINO)-4-METHYL-1-OXOPENTAN-2-YL]-4- COMPND 8 METHOXY-1H-INDOLE-2-CARBOXAMIDE SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN SARS CORONAVIRUS; SOURCE 3 ORGANISM_COMMON: SARS-COV; SOURCE 4 ORGANISM_TAXID: 694009; SOURCE 5 GENE: 1A; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS CORONAVIRUS PROTEASE INHIBITOR COMPLEX, VIRAL PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR K.S.GAJIWALA,R.A.FERRE,K.RYAN,A.E.STEWART REVDAT 5 18-OCT-23 6XHL 1 REMARK REVDAT 4 03-AUG-22 6XHL 1 COMPND HETNAM HETSYN FORMUL REVDAT 4 2 1 LINK REVDAT 3 25-NOV-20 6XHL 1 JRNL REVDAT 2 04-NOV-20 6XHL 1 JRNL REMARK REVDAT 1 08-JUL-20 6XHL 0 JRNL AUTH R.L.HOFFMAN,R.S.KANIA,M.A.BROTHERS,J.F.DAVIES,R.A.FERRE, JRNL AUTH 2 K.S.GAJIWALA,M.HE,R.J.HOGAN,K.KOZMINSKI,L.Y.LI,J.W.LOCKNER, JRNL AUTH 3 J.LOU,M.T.MARRA,L.J.MITCHELL JR.,B.W.MURRAY,J.A.NIEMAN, JRNL AUTH 4 S.NOELL,S.P.PLANKEN,T.ROWE,K.RYAN,G.J.SMITH 3RD, JRNL AUTH 5 J.E.SOLOWIEJ,C.M.STEPPAN,B.TAGGART JRNL TITL DISCOVERY OF KETONE-BASED COVALENT INHIBITORS OF CORONAVIRUS JRNL TITL 2 3CL PROTEASES FOR THE POTENTIAL THERAPEUTIC TREATMENT OF JRNL TITL 3 COVID-19. JRNL REF J.MED.CHEM. V. 63 12725 2020 JRNL REFN ISSN 0022-2623 JRNL PMID 33054210 JRNL DOI 10.1021/ACS.JMEDCHEM.0C01063 REMARK 2 REMARK 2 RESOLUTION. 1.47 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.47 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 56.61 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 74.2 REMARK 3 NUMBER OF REFLECTIONS : 76744 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.205 REMARK 3 R VALUE (WORKING SET) : 0.204 REMARK 3 FREE R VALUE : 0.223 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 3814 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.47 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.55 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 9.97 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : NULL REMARK 3 BIN R VALUE (WORKING + TEST SET) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2098 REMARK 3 BIN FREE R VALUE : 0.2376 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 78 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4648 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 68 REMARK 3 SOLVENT ATOMS : 375 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 26.67 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.37860 REMARK 3 B22 (A**2) : 0.06060 REMARK 3 B33 (A**2) : 0.31800 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.33130 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.230 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.100 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.093 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.099 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.093 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.949 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.946 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 4860 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 6606 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1664 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : 825 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 4860 ; 10.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 635 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 4377 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 0.98 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 4.00 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 14.82 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6XHL COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 19-JUN-20. REMARK 100 THE DEPOSITION ID IS D_1000250168. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 16-APR-00 REMARK 200 TEMPERATURE (KELVIN) : 98 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER X 9M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : AUTOPROC REMARK 200 DATA SCALING SOFTWARE : AUTOPROC REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 76744 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.471 REMARK 200 RESOLUTION RANGE LOW (A) : 56.600 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 74.2 REMARK 200 DATA REDUNDANCY : 3.300 REMARK 200 R MERGE (I) : 0.04700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 12.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.47 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.60 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.59800 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: BUSTER REMARK 200 STARTING MODEL: 1UK3 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.74 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.31 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PRECIPITANT: 10.0 %W/V (8.0 UL OF REMARK 280 STOCK 50.0 %W/V) PEG 6000; BUFFER: 0.1 M (4.0 UL OF STOCK 1.0 M) REMARK 280 MES (PH 6.00); ADDITIVE: 0.0 %V/V (0.0 UL OF STOCK 100.0 %V/V) REMARK 280 DIMETHYL SULFOXIDE; ADDITIVE: 10.0 % W/V (5.0 UL OF STOCK 80.0 % REMARK 280 W/V) GLYCEROL, VAPOR DIFFUSION, TEMPERATURE 294K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 49.24500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2080 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 25590 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -6.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 0 REMARK 465 SER A 1 REMARK 465 VAL A 303 REMARK 465 THR A 304 REMARK 465 PHE A 305 REMARK 465 GLN A 306 REMARK 465 GLY B 0 REMARK 465 SER B 1 REMARK 465 ASN B 277 REMARK 465 GLY B 278 REMARK 465 VAL B 303 REMARK 465 THR B 304 REMARK 465 PHE B 305 REMARK 465 GLN B 306 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH B 9185 O HOH B 9247 2.01 REMARK 500 O HOH A 9243 O HOH B 9247 2.03 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 33 -121.35 53.39 REMARK 500 ASN A 51 72.25 -153.89 REMARK 500 ASN A 84 -118.00 58.03 REMARK 500 PRO A 184 33.13 -85.23 REMARK 500 ARG A 217 19.61 -144.81 REMARK 500 ASP B 33 -125.15 55.11 REMARK 500 ASN B 51 79.67 -155.87 REMARK 500 ASN B 84 -122.02 57.52 REMARK 500 ASP B 155 12.51 59.87 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue V2M A 9001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for Di-peptide V2M B 9001 and CYS B REMARK 800 145 DBREF 6XHL A 1 306 UNP P0C6U8 R1A_CVHSA 3241 3546 DBREF 6XHL B 1 306 UNP P0C6U8 R1A_CVHSA 3241 3546 SEQADV 6XHL GLY A 0 UNP P0C6U8 EXPRESSION TAG SEQADV 6XHL GLY B 0 UNP P0C6U8 EXPRESSION TAG SEQRES 1 A 307 GLY SER GLY PHE ARG LYS MET ALA PHE PRO SER GLY LYS SEQRES 2 A 307 VAL GLU GLY CYS MET VAL GLN VAL THR CYS GLY THR THR SEQRES 3 A 307 THR LEU ASN GLY LEU TRP LEU ASP ASP THR VAL TYR CYS SEQRES 4 A 307 PRO ARG HIS VAL ILE CYS THR ALA GLU ASP MET LEU ASN SEQRES 5 A 307 PRO ASN TYR GLU ASP LEU LEU ILE ARG LYS SER ASN HIS SEQRES 6 A 307 SER PHE LEU VAL GLN ALA GLY ASN VAL GLN LEU ARG VAL SEQRES 7 A 307 ILE GLY HIS SER MET GLN ASN CYS LEU LEU ARG LEU LYS SEQRES 8 A 307 VAL ASP THR SER ASN PRO LYS THR PRO LYS TYR LYS PHE SEQRES 9 A 307 VAL ARG ILE GLN PRO GLY GLN THR PHE SER VAL LEU ALA SEQRES 10 A 307 CYS TYR ASN GLY SER PRO SER GLY VAL TYR GLN CYS ALA SEQRES 11 A 307 MET ARG PRO ASN HIS THR ILE LYS GLY SER PHE LEU ASN SEQRES 12 A 307 GLY SER CYS GLY SER VAL GLY PHE ASN ILE ASP TYR ASP SEQRES 13 A 307 CYS VAL SER PHE CYS TYR MET HIS HIS MET GLU LEU PRO SEQRES 14 A 307 THR GLY VAL HIS ALA GLY THR ASP LEU GLU GLY LYS PHE SEQRES 15 A 307 TYR GLY PRO PHE VAL ASP ARG GLN THR ALA GLN ALA ALA SEQRES 16 A 307 GLY THR ASP THR THR ILE THR LEU ASN VAL LEU ALA TRP SEQRES 17 A 307 LEU TYR ALA ALA VAL ILE ASN GLY ASP ARG TRP PHE LEU SEQRES 18 A 307 ASN ARG PHE THR THR THR LEU ASN ASP PHE ASN LEU VAL SEQRES 19 A 307 ALA MET LYS TYR ASN TYR GLU PRO LEU THR GLN ASP HIS SEQRES 20 A 307 VAL ASP ILE LEU GLY PRO LEU SER ALA GLN THR GLY ILE SEQRES 21 A 307 ALA VAL LEU ASP MET CYS ALA ALA LEU LYS GLU LEU LEU SEQRES 22 A 307 GLN ASN GLY MET ASN GLY ARG THR ILE LEU GLY SER THR SEQRES 23 A 307 ILE LEU GLU ASP GLU PHE THR PRO PHE ASP VAL VAL ARG SEQRES 24 A 307 GLN CYS SER GLY VAL THR PHE GLN SEQRES 1 B 307 GLY SER GLY PHE ARG LYS MET ALA PHE PRO SER GLY LYS SEQRES 2 B 307 VAL GLU GLY CYS MET VAL GLN VAL THR CYS GLY THR THR SEQRES 3 B 307 THR LEU ASN GLY LEU TRP LEU ASP ASP THR VAL TYR CYS SEQRES 4 B 307 PRO ARG HIS VAL ILE CYS THR ALA GLU ASP MET LEU ASN SEQRES 5 B 307 PRO ASN TYR GLU ASP LEU LEU ILE ARG LYS SER ASN HIS SEQRES 6 B 307 SER PHE LEU VAL GLN ALA GLY ASN VAL GLN LEU ARG VAL SEQRES 7 B 307 ILE GLY HIS SER MET GLN ASN CYS LEU LEU ARG LEU LYS SEQRES 8 B 307 VAL ASP THR SER ASN PRO LYS THR PRO LYS TYR LYS PHE SEQRES 9 B 307 VAL ARG ILE GLN PRO GLY GLN THR PHE SER VAL LEU ALA SEQRES 10 B 307 CYS TYR ASN GLY SER PRO SER GLY VAL TYR GLN CYS ALA SEQRES 11 B 307 MET ARG PRO ASN HIS THR ILE LYS GLY SER PHE LEU ASN SEQRES 12 B 307 GLY SER CYS GLY SER VAL GLY PHE ASN ILE ASP TYR ASP SEQRES 13 B 307 CYS VAL SER PHE CYS TYR MET HIS HIS MET GLU LEU PRO SEQRES 14 B 307 THR GLY VAL HIS ALA GLY THR ASP LEU GLU GLY LYS PHE SEQRES 15 B 307 TYR GLY PRO PHE VAL ASP ARG GLN THR ALA GLN ALA ALA SEQRES 16 B 307 GLY THR ASP THR THR ILE THR LEU ASN VAL LEU ALA TRP SEQRES 17 B 307 LEU TYR ALA ALA VAL ILE ASN GLY ASP ARG TRP PHE LEU SEQRES 18 B 307 ASN ARG PHE THR THR THR LEU ASN ASP PHE ASN LEU VAL SEQRES 19 B 307 ALA MET LYS TYR ASN TYR GLU PRO LEU THR GLN ASP HIS SEQRES 20 B 307 VAL ASP ILE LEU GLY PRO LEU SER ALA GLN THR GLY ILE SEQRES 21 B 307 ALA VAL LEU ASP MET CYS ALA ALA LEU LYS GLU LEU LEU SEQRES 22 B 307 GLN ASN GLY MET ASN GLY ARG THR ILE LEU GLY SER THR SEQRES 23 B 307 ILE LEU GLU ASP GLU PHE THR PRO PHE ASP VAL VAL ARG SEQRES 24 B 307 GLN CYS SER GLY VAL THR PHE GLN HET V2M A9001 34 HET V2M B9001 34 HETNAM V2M N-[(2S)-1-({(2S,3S)-3,4-DIHYDROXY-1-[(3S)-2- HETNAM 2 V2M OXOPYRROLIDIN-3-YL]BUTAN-2-YL}AMINO)-4-METHYL-1- HETNAM 3 V2M OXOPENTAN-2-YL]-4-METHOXY-1H-INDOLE-2-CARBOXAMIDE HETSYN V2M N-[(2S)-1-({(2S)-4-HYDROXY-3-OXO-1-[(3S)-2- HETSYN 2 V2M OXOPYRROLIDIN-3-YL]BUTAN-2-YL}AMINO)-4-METHYL-1- HETSYN 3 V2M OXOPENTAN-2-YL]-4-METHOXY-1H-INDOLE-2-CARBOXAMIDE, HETSYN 4 V2M BOUND FORM FORMUL 3 V2M 2(C24 H34 N4 O6) FORMUL 5 HOH *375(H2 O) HELIX 1 AA1 SER A 10 GLY A 15 1 6 HELIX 2 AA2 HIS A 41 CYS A 44 5 4 HELIX 3 AA3 GLU A 47 ASN A 51 5 5 HELIX 4 AA4 ASN A 53 ARG A 60 1 8 HELIX 5 AA5 SER A 62 HIS A 64 5 3 HELIX 6 AA6 ILE A 200 ASN A 214 1 15 HELIX 7 AA7 THR A 226 TYR A 237 1 12 HELIX 8 AA8 THR A 243 LEU A 250 1 8 HELIX 9 AA9 LEU A 250 GLY A 258 1 9 HELIX 10 AB1 ALA A 260 GLY A 275 1 16 HELIX 11 AB2 THR A 292 GLY A 302 1 11 HELIX 12 AB3 SER B 10 GLY B 15 1 6 HELIX 13 AB4 HIS B 41 CYS B 44 5 4 HELIX 14 AB5 ALA B 46 ASN B 51 5 6 HELIX 15 AB6 ASN B 53 ARG B 60 1 8 HELIX 16 AB7 SER B 62 PHE B 66 5 5 HELIX 17 AB8 ILE B 200 ASN B 214 1 15 HELIX 18 AB9 THR B 226 TYR B 237 1 12 HELIX 19 AC1 THR B 243 LEU B 250 1 8 HELIX 20 AC2 LEU B 250 GLY B 258 1 9 HELIX 21 AC3 ALA B 260 GLY B 275 1 16 HELIX 22 AC4 THR B 292 SER B 301 1 10 SHEET 1 AA1 7 VAL A 73 LEU A 75 0 SHEET 2 AA1 7 PHE A 66 ALA A 70 -1 N VAL A 68 O LEU A 75 SHEET 3 AA1 7 MET A 17 CYS A 22 -1 N THR A 21 O LEU A 67 SHEET 4 AA1 7 THR A 25 LEU A 32 -1 O LEU A 27 N VAL A 20 SHEET 5 AA1 7 THR A 35 PRO A 39 -1 O TYR A 37 N LEU A 30 SHEET 6 AA1 7 LEU A 86 VAL A 91 -1 O LEU A 89 N VAL A 36 SHEET 7 AA1 7 VAL A 77 GLN A 83 -1 N GLN A 83 O LEU A 86 SHEET 1 AA2 5 LYS A 100 PHE A 103 0 SHEET 2 AA2 5 CYS A 156 GLU A 166 1 O VAL A 157 N LYS A 100 SHEET 3 AA2 5 VAL A 148 ASP A 153 -1 N ASN A 151 O SER A 158 SHEET 4 AA2 5 THR A 111 TYR A 118 -1 N SER A 113 O PHE A 150 SHEET 5 AA2 5 SER A 121 ALA A 129 -1 O TYR A 126 N VAL A 114 SHEET 1 AA3 3 LYS A 100 PHE A 103 0 SHEET 2 AA3 3 CYS A 156 GLU A 166 1 O VAL A 157 N LYS A 100 SHEET 3 AA3 3 HIS A 172 THR A 175 -1 O ALA A 173 N MET A 165 SHEET 1 AA4 7 VAL B 73 LEU B 75 0 SHEET 2 AA4 7 LEU B 67 ALA B 70 -1 N ALA B 70 O VAL B 73 SHEET 3 AA4 7 MET B 17 CYS B 22 -1 N THR B 21 O LEU B 67 SHEET 4 AA4 7 THR B 25 LEU B 32 -1 O LEU B 27 N VAL B 20 SHEET 5 AA4 7 THR B 35 PRO B 39 -1 O THR B 35 N LEU B 32 SHEET 6 AA4 7 LEU B 86 VAL B 91 -1 O LEU B 87 N CYS B 38 SHEET 7 AA4 7 VAL B 77 GLN B 83 -1 N SER B 81 O ARG B 88 SHEET 1 AA5 5 LYS B 100 PHE B 103 0 SHEET 2 AA5 5 CYS B 156 GLU B 166 1 O VAL B 157 N LYS B 100 SHEET 3 AA5 5 VAL B 148 ASP B 153 -1 N ASN B 151 O SER B 158 SHEET 4 AA5 5 THR B 111 TYR B 118 -1 N SER B 113 O PHE B 150 SHEET 5 AA5 5 SER B 121 ALA B 129 -1 O SER B 123 N ALA B 116 SHEET 1 AA6 3 LYS B 100 PHE B 103 0 SHEET 2 AA6 3 CYS B 156 GLU B 166 1 O VAL B 157 N LYS B 100 SHEET 3 AA6 3 HIS B 172 THR B 175 -1 O ALA B 173 N MET B 165 LINK SG CYS A 145 C34 V2M A9001 1555 1555 1.84 LINK SG CYS B 145 C34 V2M B9001 1555 1555 1.84 CISPEP 1 LEU B 282 GLY B 283 0 -14.34 SITE 1 AC1 17 HIS A 41 PHE A 140 LEU A 141 ASN A 142 SITE 2 AC1 17 GLY A 143 SER A 144 CYS A 145 HIS A 163 SITE 3 AC1 17 HIS A 164 MET A 165 GLU A 166 HIS A 172 SITE 4 AC1 17 GLN A 189 THR A 190 ALA A 191 HOH A9171 SITE 5 AC1 17 HOH A9209 SITE 1 AC2 18 LEU B 27 ASN B 28 HIS B 41 PHE B 140 SITE 2 AC2 18 ASN B 142 GLY B 143 SER B 144 GLY B 146 SITE 3 AC2 18 SER B 147 HIS B 163 HIS B 164 MET B 165 SITE 4 AC2 18 GLU B 166 HIS B 172 GLN B 189 THR B 190 SITE 5 AC2 18 HOH B9161 HOH B9175 CRYST1 55.770 98.490 59.630 90.00 108.31 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017931 0.000000 0.005934 0.00000 SCALE2 0.000000 0.010153 0.000000 0.00000 SCALE3 0.000000 0.000000 0.017664 0.00000